<DOC>
	<DOCNO>NCT02373176</DOCNO>
	<brief_summary>[ 14C ] PRC-4016 ( Icosabutate ) - A Phase I , Open-Label Study Absorption , Metabolism Excretion Following Oral Dosing Healthy Male Subjects . Objective : To evaluate pharmacokinetics total radioactivity blood plasma PRB-01022 ( icosabutate ) ( unchanged drug ) plasma follow single oral administration [ 14C ] PRC-4016 healthy male subject . To obtain mass balance oral [ 14C ] PRC-4016 quantifying urinary faecal excretion radioactivity . To examine profile metabolite plasma , urine faeces . To assess safety tolerability single oral dose [ 14C ] PRC 4016 healthy male subject .</brief_summary>
	<brief_title>14C Icosabutate -A Phase I Absorption , Metabolism Excretion Study</brief_title>
	<detailed_description />
	<criteria>male ethnic origin age 3560 BMI 1835 kg/m2 generally good health sign informed consent subject subject partner willing use appropriate contraception subject receive prescribed systemic topical medication within 14 day dose subject use nonprescribed systemic topical medication within 7 day dose subject receive medication incl . St. Johns Worth within 30 day dose administration . subject participate clinical trial currently within past 3 month . recent blood donation history drug allergy clinically significant allergic disease BP pulse outside reference range high consumption alcohol high consumption og tobacco clinically significant disorder clinically significant disease within 4 week dose . serum hepatitis , HIV abnormal ECG subject expose radiation result occupation subject receive radiolabelled material within 12 month subject earlier take part study withdrawn study ot suitable enrolment accord investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>